On June 29, 2016, the U.S. Food and Drug Administration approved Kovanaze™ (St. Renatus, L.L.C.), a needleless, intranasally administered spray combination of the ester anesthetic tetracaine HCl plus the vasoconstrictor oxymetazoline HCl (6 mg/0.1 mg per 0.2 mL) for regional maxillary anesthesia.1
OSAP Disclaimer | Please notify our webmaster of any problems with this website. OSAP thanks its Super Sponsors for their support in 2017. Sponsorship does not imply endorsement by OSAP of a company's products or services.